Monday, September 25, 2006 by: NewsTarget
Tags: health news, Natural News, nutrition
Ezekiel Emanuel, Chair of the Department of Clinical Bioethics, Clinical Center, National Institutes of Health, argues that "the crucial question is whether an IRB, regardless of its tax status, is performing at a high level of quality." We should, he says, "dump the outdated ideology of 'for-profit bad, not-for-profit good'" and focus instead on how the IRB is performing in its ethics reviews.
Emanuel argues that there are several examples of for-profit IRBs that are performing reviews just as well as, or better than, non-profit academic centers.
"The first IRBs to receive 'full accreditation'--the highest level of accreditation awarded by the Association for the Accreditation of Human Research Protection Programs-- were one for-profit IRB, Western Institutional Review Board (WIRB), and one not-for-profit IRB, University of Iowa," says Emanuel. "And so it continued: of the first eight organizations to receive full accreditation, four were for-profit IRBs."
However, Trudo Lemmens (Associate Professor, Faculty of Law, University of Toronto) and Carl Elliot (Professor, Center for Bioethics, University of Minnesota) argue that commercial IRBs have a fundamental conflict of interest, because "they are in a client–provider business relationship with the commercial entities whose studies they review. Because commercial IRBs generate their income from clients with a direct financial interest in obtaining approval, they are affected by the very problem they are expected to curtail."
The financial interests involved are huge, they say. "Clinical trials are a crucial step in the drug development process. Any delay in approval by an IRB affects the sponsor's profit margins."
Lemmens and Elliot say that the countries that have allowed private IRBs to flourish have also failed to regulate them carefully: "Anyone who can bring together five people, including a community representative, a physician, a lawyer and an 'ethicist,' can set up shop and start competing for business."
Citation: Emanuel EJ, Lemmens T, Elliot C (2006) Should society allow research ethics boards to be run as for-profit enterprises? PLoS Med 3(7): e309.
http://www.plos.org/press/plme-03-07-emanuel.pdf
Contacts:
Ezekiel Emanuel National Institutes of Health Clinical Bioethics Department (HNJ4) 10 Center DR MSC 1156 Building 10 Room 1C133 Bethesda, MD 20892, United States of America +1 301 435 8706 [email protected]
Trudo Lemmens University of Toronto Faculty of Law 78 Queen's Park Toronto, Ontario M52C5 Canada +1 416-978-4201 [email protected]
Carl Elliott University of Minnesota Center for Bioethics N504 Boynton 410 Church Street SE Minneapolis, MN 55455-0346 United States of America [email protected]
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more.
Permalink to this article:
Embed article link: (copy HTML code below):
Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.
Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest
"Big Tech and mainstream media are constantly trying to silence the independent voices that dare to bring you the truth about toxic food ingredients, dangerous medications and the failed, fraudulent science of the profit-driven medical establishment.
Email is one of the best ways to make sure you stay informed, without the censorship of the tech giants (Google, Apple, Facebook, Twitter, YouTube, etc.). Stay informed and you'll even likely learn information that may help save your own life."
–The Health Ranger, Mike Adams